We build staff as projects mature and needs are delineated.
Donations may be earmarked for projects the donor wishes to support and otherwise will be applied at the discretion of KRF to core structural needs or to project support. Overhead is deliberately kept low to maximize the potency of donations.
Support our transformative work by donating below.
KRF excels in Research, Education and Training with Ketamine, Ketamine Assisted Psychotherapy and Psychoactive and Psychedelic Methodologies
Overview: As we are able to design and perform research within the legal status of ketamine—WHO/worldwide –we are in the process of developing protocols to be funded and administered under KRF’s non-profit umbrella. We are welcoming of new creative initiatives and are developing relations with collaborating researchers. Each project has its own cost center and donations to KRF may be earmarked. Studies are IRB approved and registered.
Our New Initiative – in Formation:
Protocol for Ketamine Treatment of Acute Emotional Trauma and Distress
The International Consultation Group for the Treatment of Acute Trauma with Ketamine and Other Therapeutic Modalities (ICG).
In awareness of ketamine’s potential for the treatment of acute agitation, suicidality, and PTSD, and in response to the many horrors being visited on humans, we have just begun the development of ketamine protocols for the treatment of emotional reactions to acute traumatization. We have sent out our initial protocol as widely as possible in an effort to provide a guide to ketamine’s use as a therapeutics applicable to acute trauma. KRF is serving as an initiator and a ground to which practitioners may turn. This is a collaboration and to that end we are building an international body, what we are calling the ICG, to create the conditions for applying ketamine and other modalities for acute care. This is unprecedented and we are in need of developing a literature to validate our methodology. Developing the protocol with intensive feedback from those on the ground is essential. This is a cooperative project and will grow in its scope and needs. It is created in the spirit of service and beyond borders with the intention of caring, kindness and sharing.
$25,000 initial budget
KAP for Conscious Dying/ Conscious Living—with its own unique measure for assessing goals, feelings, and conflicts at the end of life, –the ELI. We are now coordinating our research as a five-center study with 120 Subjects–for those who have one year or less of life expectancy. We have begun enrolling subjects. This is an intensive demonstration of the benefits of KAP in consciously preparing for remaining life and ultimate death and is intended to serve as a humanizing model for palliative care and hospice programs. It is FDA and IRB approved with unique breakthroughs in the utilization of ketamine with the FDA.
$900,000 is our budget
Ketamine for Menstrually Related Disorders—PMS and PMDD
KRF has focused on Women’s Health and wellbeing with a new project to demonstrate the effectiveness of ketamine for PMS and PMDD. We have begun the process of submitting for FDA approval. Previously, based on our clinical experience through our sister Center for Transformational Psychotherapy, we conducted a small study demonstrating the extraordinary effectiveness of low dose ketamine given in response to the arising of symptoms of PMS/PMDD. This led to a use patent for this indication, the benefit of patenting being widespread access. It is our strong belief that women worldwide will benefit from episodic use on an intermittent basis with provision for at-home administration as needed, This is a breakthrough for women suffering in the luteal phase of the menstrual cycle providing a restitution of well-being and presence.
$150,000 is our budget
The Pharmacokinetics of the Sublingual Lozenge
The sublingual lozenge (SL) that is in widespread clinical use, much of it controversial with respect to standard of care—FDA just issued a warning about this—was developed by Phil Wolfson in collaboration for its formulation with Peter Koshland. The formula was offered freely and has been replicated and has had dosage augmentation by some. We have always favored the SL form over the intranasal form as it has minimal abuse potential. Its absorption through the mucosal linings of the mouth depends on the length of time it is held there. Various recommendations have been made for duration, some of them in the interest of selling more product. Our consistent recommendation has been for 15 minutes. Essential to our research and our clinical practice—and as a data based recommendation based on our findings, we are preparing to conduct a pharmacokinetic study, utilizing the lab at UCSF for our analytics, as we did for the Lactation Study. The study undoubtedly will benefit research and clinical practices as well as inform the public about standard of care.
$200,000 is our budget
The Post-Partum Depression Protocol
The Foundation has patented the use of ketamine for Post-Partum Depression (PPD) which is novel. We are developing commercialization with an exclusive contract with PTI for which we have received equity. We are in protocol development for a multi-site PPD KAP model treatment program which we believe will demonstrate great success in benefitting new mothers without affecting breast feeding or exposing infants to medications. Our groundbreaking ketamine and lactation study has assured us of this. Anticipated project initiation is in Spring 2024. There Is great interest in this as a significant new treatment for women suffering with PPD.
$1,000,000 is our budget
The Veterans Co-Facilitator Training Program in coalition with Heroic Hearts
Will move into operation at the beginning of 2024. This is a major and unique initiative to transform the treatment of PTSD for vets using a KAP group model in a 3-month long experience to develop vets themselves to be co-facilitators for an expanded PTSD program that is facilitated by those who have military experience. As we move to Phase 2 our intention is to have this serve as a demonstration affecting positively the treatment of vets by the VA and other institutions. Goal $200,000.
We have redesigned our logo and websites and developing funding campaigns and public awareness of who we are and what we do.
All of this goes to our need for basic structure. We are a lean outfit. We build staff as projects mature and needs are delineated. As our programs grow and are activated, we are in need of new staff and the stuff of making an organization thrive. We appreciate donations that contribute to our structure.
There is much more in process, and we encourage donors to participate in our work and become familiar with what we do and who we are.
Your donations are greatly appreciated!
Hugs and love,
Phil Wolfson MD — Founder and CEO